oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2020 ( 19 )

2019 ( 246 )

2018 ( 288 )

2017 ( 313 )

Custom range...

Search Results: 1 - 10 of 138831 matches for " K. Crum "
All listed articles are free for downloading (OA Articles)
Page 1 /138831
Display every page Item
Comments on "Evidence for Nuclear Emissions During Acoustic Cavitation" by R.P. Taleyarkhan et al., Science volume 295,p.1868, March 8, 2002
S. J. Putterman,L. A. Crum,K. Suslick
Physics , 2002,
Abstract: In a paper recently published in Science, Taleyarkhan et al. claimed to observe fusion from acoustic cavitation and the associated phenomenon of sonoluminescence. Although, this is a worthwhile line of investigation we explain why, in our opinion, their data neither proves nor disproves this possibility.
TOWARDS EFFECTIVE AND ACCOUNTABLE LEADERSHIP OF THE UNION- OPTIONS AND GUIDELINES FOR REFORM (PART TWO)
Wouter Coussens,Ben Crum
Romanian Journal of European Affairs (RJEA) , 2003,
Abstract: The success of the Convention on the future of the EU will to a great extent depend upon on its answers to the institutional questions. Among these questions, the issue of EU leadership plays a crucial role. In this paper, three challenges for the re-organisation of leadership in the Union are identified:- Union leadership has to be more effective;- Leadership in the Union should contribute to the democratic character of the Union;- Leadership reform should not fundamentally distort the Union’s institutional balance.In view of these three challenges, the authors consider the two main strands of debate that touch upon the issue of leadership in the EU: first, the debate on the election of the Commission President and, secondly, the different proposals for reforming the Council Presidency
TOWARDS EFFECTIVE AND ACCOUNTABLE LEADERSHIP OF THE UNION. OPTIONS AND GUIDELINES FOR REFORM
Wouter Coussens,Ben Crum
Romanian Journal of European Affairs (RJEA) , 2003,
Abstract: The success of the Convention on the future of the EU will to a great extent depend upon its answers to the institutional questions. Among these questions, the issue of EU leadership plays a crucial role. In this paper, three challenges for the re-organisation of leadership in the Union are identified:- Union leadership has to be more effective;- Leadership in the Union should contribute to the democratic character of the Union;- Leadership reform should not fundamentally distort the Union s institutional balance.In view of these three challenges, the authors consider the two main strands of debate that touch upon the issue of leadership in the EU: first, the debate on the election of the Commission President and, secondly, the different proposals for reforming the Council Presidency.
Associated Sturm-Liouville systems
M. M. Crum
Physics , 1999,
Abstract: Crum's seminal result of 1955 is archived here
Increasing Rates of Obesity among HIV-Infected Persons during the HIV Epidemic
Nancy Crum-Cianflone,Mollie Poehlman Roediger,Lynn Eberly,Maryam Headd,Vincent Marconi,Anuradha Ganesan,Amy Weintrob,R. Vincent Barthel,Susan Fraser,Brian K. Agan
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0010106
Abstract: The prevalence and factors associated with overweight/obesity among human immunodeficiency virus (HIV)-infected persons are unknown.
Identification of an Abbreviated Test Battery for Detection of HIV-Associated Neurocognitive Impairment in an Early-Managed HIV-Infected Cohort
David J. Moore,Mollie J. P. Roediger,Lynn E. Eberly,Kaitlin Blackstone,Braden Hale,Amy Weintrob,Anuradha Ganesan,Brian K. Agan,Scott L. Letendre,Nancy F. Crum-Cianflone
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0047310
Abstract: HIV-associated neurocognitive disorders (HAND) remain prevalent despite improved antiretroviral treatment (ART), and it is essential to have a sensitive and specific HAND screening tool.
The Effect of Human Immunodeficiency Virus on Hepatitis B Virus Serologic Status in Co-Infected Adults
Michael L. Landrum,Ann M. Fieberg,Helen M. Chun,Nancy F. Crum-Cianflone,Vincent C. Marconi,Amy C. Weintrob,Anuradha Ganesan,Robert V. Barthel,Glenn Wortmann,Brian K. Agan
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0008687
Abstract: Factors associated with serologic hepatitis B virus (HBV) outcomes in HIV-infected individuals remain incompletely understood, yet such knowledge may lead to improvements in the prevention and treatment of chronic HBV infection.
Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS
Vincent C. Marconi,Greg Grandits,Jason F. Okulicz,Glenn Wortmann,Anuradha Ganesan,Nancy Crum-Cianflone,Michael Polis,Michael Landrum,Matthew J. Dolan,Sunil K. Ahuja,Brian Agan,Hemant Kulkarni
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0017956
Abstract: The impact of viral load (VL) decay and cumulative VL on CD4 recovery and AIDS after highly-active antiretroviral therapy (HAART) is unknown.
Hepatitis B Vaccine Antibody Response and the Risk of Clinical AIDS or Death
Michael L. Landrum, Katherine Huppler Hullsiek, Robert J. O'Connell, Helen M. Chun, Anuradha Ganesan, Jason F. Okulicz, Tahaniyat Lalani, Amy C. Weintrob, Nancy F. Crum-Cianflone, Brian K. Agan, and Infectious Disease Clinical Research Program HIV Working Group
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0033488
Abstract: Background Whether seroresponse to a vaccine such as hepatitis B virus (HBV) vaccine can provide a measure of the functional immune status of HIV-infected persons is unknown.This study evaluated the relationship between HBV vaccine seroresponses and progression to clinical AIDS or death. Methods and Findings From a large HIV cohort, we evaluated those who received HBV vaccine only after HIV diagnosis and had anti-HBs determination 1–12 months after the last vaccine dose. Non-response and positive response were defined as anti-HBs <10 and ≥10 IU/L, respectively. Participants were followed from date of last vaccination to clinical AIDS, death, or last visit. Univariate and multivariable risk of progression to clinical AIDS or death were evaluated with Cox regression models. A total of 795 participants vaccinated from 1986–2010 were included, of which 41% were responders. During 3,872 person-years of observation, 122 AIDS or death events occurred (53% after 1995). Twenty-two percent of non-responders experienced clinical AIDS or death compared with 5% of responders (p<0.001). Non-response to HBV vaccine was associated with a greater than 2-fold increased risk of clinical AIDS or death (HR 2.47; 95% CI, 1.38–4.43) compared with a positive response, after adjusting for CD4 count, HIV viral load, HAART use, and delayed type hypersensitivity skin test responses (an in vivo marker of cell-mediated immunity). This association remained evident among those with CD4 count ≥500 cells/mm3 (HR 3.40; 95% CI, 1.39–8.32). Conclusions HBV vaccine responses may have utility in assessing functional immune status and risk stratificating HIV-infected individuals, including those with CD4 count ≥500 cells/mm3.
Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort
Alan R Lifson, Elizabeth M Krantz, Lynn E Eberly, Matthew J Dolan, Vincent C Marconi, Amy C Weintrob, Nancy F Crum-Cianflone, Anuradha Ganesan, Patricia L Grambsch, Brian K Agan, the Infectious Disease Clinical Research Program (IDCRP) HIV Working Group
AIDS Research and Therapy , 2011, DOI: 10.1186/1742-6405-8-2
Abstract: To address this question and identify other determinants of CD4+ response, we analyzed data for 1,846 persons from a prospective HIV military cohort study who initiated HAART, who had post-HAART CD4+ measurements, and for whom HIV seroconversion (SC) date was estimated.CD4+ count at HAART initiation was ≤ 200 cells/mm3 for 23%, 201-349 for 31%, 350-499 for 27%, and ≥500 for 19%. The first 6 months post-HAART, the greatest CD4+ increases (93-151 cells) occurred, with lesser increases (22-36 cells/year) through the first four years. Although CD4+ changes for the entire cohort were relatively flat thereafter, HIV viral load (VL) suppressors showed continued increases of 12-16 cells/year. In multivariate analysis adjusting for baseline CD4+ and post-HAART time interval, CD4+ responses were poorer in those with: longer time from HIV SC to HAART start, lower pre-HAART CD4+ nadir, higher pre-HAART VL, and clinical AIDS before HAART (P < 0.05).Small but positive long-term increases in CD4+ count in virally suppressed patients were observed. CD4+ response to HAART is influenced by multiple factors including duration of preceding HIV infection, and optimized if treatment is started with virally suppressive therapy as early as possible.Among those with human immunodeficiency virus (HIV) infection, the CD4+ T-lymphocyte count is the major indicator of immunodeficiency, a main factor in deciding whether to initiate highly active antiretroviral therapy (HAART), and an important parameter in monitoring treatment response [1,2]. Failure to restore a normal CD4+ count following HAART is associated with increased morbidity due to both AIDS and non-AIDS events, as well as increased mortality [3-5].Studies of the kinetics of CD4+ count response post-HAART indicate that the CD4+ count increases rapidly during the first 3-6 months, in part due to release of memory T-cells from lymphoid tissue, and then increases slowly during the next 3-4 years, reflecting reconstitution of the immune sy
Page 1 /138831
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.